Laurus Labs's unit ImmunoACT got approval for Nexcar19 for the treatment of relapsed/refractory B-cell lymphomas and leukemia.
∙Consolidated net profit came at Rs 45.7 cr vs Rs 47.5 cr (YoY). ∙Revenue came at Rs 277 cr vs Rs 290 cr (YoY). ∙EBITDA was at Rs 43 cr vs Rs 37.8 cr (YoY). ∙EBITDA Margin was 15.55% vs 13.16% (YoY).
NLC India has created a new subsidiary, "NLC India Green Energy Ltd," for future renewable energy projects.
Swipe up to